Elicio Therapeutics, Inc.
ELTX · XNASCIK 1601485fmd_1N488NFWBHKF1THANAAX7BS246Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 3 | 28 | 2 | – | – | – |
| Cost of revenue | 1 | 0 | 0 | – | – | – |
| Net interest income | (9) | (2) | 1 | – | – | – |
| Gross profit | 2 | 28 | 2 | – | – | – |
| Research and development | 39 | 49 | 18 | 24 | 34 | 25 |
| Operating income | (55) | (39) | (24) | (36) | (45) | (38) |
| Interest expense | – | – | 4 | 1 | 0 | 1 |
| Other non-operating income (expense) | (25) | (15) | (4) | 1 | (7) | (2) |
| Income before taxes | (80) | (55) | (39) | – | (52) | (40) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (80) | (55) | (39) | – | (52) | (40) |
| Net income | (80) | (55) | (28) | (35) | (52) | (40) |